Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.

Cancer letters - 28 Aug 2024

Nakamura Ryota, Yamada Tadaaki, Tokuda Shinsaku, Morimoto Kenji, Katayama Yuki, Matsui Yohei, Hirai Soichi, Ishida Masaki, Kawachi Hayato, Sawada Ryo, Tachibana Yusuke, Osoegawa Atsushi, Horinaka Mano, Sakai Toshiyuki, Yasuhiro Tomoko, Kozaki Ryohei, Yano Seiji, Takayama Koichi

Abstract excerpt

We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in high-AXL-expressing EGFR-mutated non-small cell lung cancer (NSCLC) cells. Nevertheless, certain residual cells are anticipated to eventually develop acquired resistance to this combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Axl Receptor Tyrosine Kinase

Share to Phenylurea Compounds

Share to Piperazines

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Triazoles

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 39059573
DOI: 10.1016/j.canlet.2024.217124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.PMID 39059573Read ↗

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer CellsSemantic proximity Read ↗

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.Semantic proximity Read ↗

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.Semantic proximity Read ↗

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.Semantic proximity Read ↗

Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.Semantic proximity Read ↗

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells.Semantic proximity Read ↗

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.Semantic proximity Read ↗

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistanceSemantic proximity Read ↗

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.